Mirum Raises 2026 Net Product Sales Guidance to $715 Million-$720 Million
Photo: TokenPost
Mirum Pharmaceuticals, Inc. raised its 2026 net product sales guidance to $715 million to $720 million and said it is targeting positive cash flow in 2027 after third-quarter net product sales reached $186 million. The company said commercial performance and pipeline progress underpin its cash-flow target. Its commercial business had a cash contribution margin in the high 50s as a percentage of sales in the third quarter. Cash used in operations was about $4 million, and Mirum held approximately $500 million in cash, equivalents and investments.
Source: TokenPost
